Predictive value of natriuretic peptides in dogs with mitral valve disease

被引:62
|
作者
Tarnow, Inge [1 ]
Olsen, Lisbeth H. [1 ]
Kvart, Clarence [2 ]
Hoglund, Katja [2 ]
Moesgaard, Sophia G. [1 ]
Kamstrup, Thea S. [1 ]
Pedersen, Henrik D. [3 ]
Haggstrom, Jens [4 ]
机构
[1] Univ Copenhagen, Dept Basic Anim & Vet Sci, Fac Life Sci, DK-1870 Frederiksberg C, Denmark
[2] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Fac Vet Med & Anim Sci, S-75007 Uppsala, Sweden
[3] Zealand Pharma AS, DK-2600 Glostrup, Denmark
[4] Swedish Univ Agr Sci, Dept Clin Sci, Fac Vet Med & Anim Sci, S-75007 Uppsala, Sweden
基金
英国医学研究理事会;
关键词
NT-proANP; NT-proBNP; Mitral regurgitation; Heart failure; Cavalier King Charles Spaniels; CONGESTIVE-HEART-FAILURE; CARDIAC TROPONIN-I; PLASMA ATRIAL; GENE-EXPRESSION; ECHOCARDIOGRAPHY; REGURGITATION; DIAGNOSIS; OVERLOAD; DYSPNEA; STRETCH;
D O I
10.1016/j.tvjl.2007.12.026
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Natriuretic peptides are useful in diagnosing heart failure in dogs. However, their usefulness in detecting early stages of myxomatous mitral valve disease (MMVD) has been debated. This study evaluated N-terminal (NT) fragment pro-atrial natriuretic peptide (NT-proANP) and NT-pro-brain natriuretic peptide (NT-proBNP) in 39 Cavalier King Charles Spaniels (CKCS) with pre-clinical mitral valve regurgitation (MR), sixteen dogs with clinical signs of heart failure (HF) and thirteen healthy control dogs. Twenty seven CKCS and tell control dogs were re-examined 4 years after the initial examination and the status of the dogs 5 years after the initial examination was determined by telephone calls to the owner. All dogs were evaluated by clinical examination and echocardiography. CKCS with severe MR had higher NT-proANP and NT-proBNP compared to controls and CKCS with less severe MR. Dogs with clinical signs of HF had markedly elevated NT-proANP and NT-proBNP. Plasma concentrations of the natriuretic peptides measured at re-examination could predict progression in regurgitant jet size. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 50 条
  • [41] Effect of atorvastatin on oxidative stress and inflammation markers in myxomatous mitral valve disease in dogs: A comparison of subclinical and clinical stages
    Thassakorn, Patchaya
    Patchanee, Papras
    Pongkan, Wanpitak
    Chattipakorn, Nipon
    Boonyapakorn, Chavalit
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2019, 42 (03) : 258 - 267
  • [42] Clinical Severity Score System in Dogs with Degenerative Mitral Valve Disease
    Lopez-Alvarez, J.
    Elliott, J.
    Pfeiffer, D.
    Chang, Y. -M.
    Mattin, M.
    Moonarmart, W.
    Hezzell, M. J.
    Boswood, A.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2015, 29 (02): : 575 - 581
  • [43] Renal Resistive Index in 55 Dogs with Degenerative Mitral Valve Disease
    Chetboul, V.
    Daste, T.
    Gouni, V.
    Concordet, D.
    Trehiou-Sechi, E.
    Serres, F.
    Pouchelon, J. L.
    Germain, C. A.
    Layssol-Lamour, C.
    Lefebvre, H. P.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2012, 26 (01) : 101 - 108
  • [44] Evaluation of new and old biomarkers in dogs with degenerative mitral valve disease
    Klein, Stephanie
    Nolte, Ingo
    Granados-Soler, Jose Luis
    Lietz, Philipp
    Sehn, Maximiliane
    Raue, Jonathan Friedemann
    Rohn, Karl
    Packeiser, Eva-Maria
    Bach, Jan-Peter
    BMC VETERINARY RESEARCH, 2022, 18 (01)
  • [45] Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease
    Ames, M. K.
    Atkins, C. E.
    Eriksson, A.
    Hess, A. M.
    JOURNAL OF VETERINARY CARDIOLOGY, 2017, 19 (03) : 218 - 227
  • [46] Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study
    Boswood, A.
    Gordon, S. G.
    Haggstrom, J.
    Wess, G.
    Stepien, R. L.
    Oyama, M. A.
    Keene, B. W.
    Bonagura, J.
    MacDonald, K. A.
    Patteson, M.
    Smith, S.
    Fox, P. R.
    Sanderson, K.
    Woolley, R.
    Szatmari, V.
    Menaut, P.
    Church, W. M.
    O'Sullivan, M. L.
    Jaudon, J. -P.
    Kresken, J. -G.
    Rush, J.
    Barrett, K. A.
    Rosenthal, S. L.
    Saunders, A. B.
    Ljungvall, I.
    Deinert, M.
    Bomassi, E.
    Estrada, A. H.
    Fernandez Del Palacio, M. J.
    Moise, N. S.
    Abbott, J. A.
    Fujii, Y.
    Spier, A.
    Luethy, M. W.
    Santilli, R. A.
    Uechi, M.
    Tidholm, A.
    Schummer, C.
    Watson, P.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2018, 32 (01): : 72 - 85
  • [47] Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
    Valente, Carlotta
    Guglielmini, Carlo
    Toaldo, Marco Baron
    Romito, Giovanni
    Artusi, Carlo
    Brugnolo, Laura
    Contiero, Barbara
    Poser, Helen
    FRONTIERS IN VETERINARY SCIENCE, 2021, 8
  • [48] Pharmacologic management of myxomatous mitral valve disease in dogs
    Atkins, Clarke E.
    Haggstrom, Jens
    JOURNAL OF VETERINARY CARDIOLOGY, 2012, 14 (01) : 165 - 184
  • [49] Left atrial size and contractile function in healthy dogs and dogs with chronic mitral valve disease
    Petrus, Lilian C.
    Castro, Jacqueline R.
    Mantovani, Matheus M.
    Gimenes, Andre M.
    Duarte, Caio N.
    Goldfeder, Guilherme T.
    Schwartz, Denise S.
    Larsson, Maria Helena M. A.
    PESQUISA VETERINARIA BRASILEIRA, 2018, 38 (08): : 1622 - 1630
  • [50] Effects of mitral valve repair on valvular geometry and hemodynamics in dogs with myxomatous mitral valve disease
    Mihara, Kippei
    Kanemoto, Isamu
    Sato, Keiichi
    Yasuhira, Yuma
    Watanabe, Itsuki
    Suzuki, Yuya
    Nagura, Jumpei
    Misumi, Kazuhiro
    VETERINARY SURGERY, 2024, 53 (03) : 415 - 425